Novo Nordisk (NVO) stock tumbled Monday after its experimental weight-loss drug, CagriSema, failed to top its rival from Eli Lilly (LLY) in a Phase 3 study.
XNOW PLAYINGThe Weight-Loss Drug Market I… [+2072 chars]
Novo Nordisk Dives 9%. Why Eli Lilly Now Has The Upper Hand. - Investor's Business Daily
Novo Nordisk's experimental obesity drug failed to top Eli Lilly's Zepbound. But there's something else that rattled investors.
By:ALLISON GATLIN, Investor's Business Daily
Source:Investor's Business Daily
Published:
Related News
Speculation Mounts Japan to Buy Yen, Perhaps With US Help - Bloomberg
Speculation mounted into the weekend that Japanese authorities could be preparing to enter currency markets in a bid to halt the yen’s slide, possibly with the rare assistance of the US.
Bloomberg•Carter Johnson
TikTok users freak out over app’s ‘immigration status’ collection — here’s what it means - TechCrunch
TikTok users are freaking out over a mention of "immigration status" data collection, but lawyers explain the disclosure is related to state privacy laws.
TechCrunch•Sarah Perez
Car crashes through glass doors of Delta check-in at DTW - detroitnews.com
Social media posts of a video showing a car inside the terminal and check-in area were circulating. Another video showed a man who was yelling being forcibly removed from the area of the crash.
The Detroit News•Jennifer Chambers